febuxostat
Selected indexed studies
- Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. (Lancet, 2020) [PMID:33181081]
- Febuxostat compared with allopurinol in patients with hyperuricemia and gout. (N Engl J Med, 2005) [PMID:16339094]
- Febuxostat. (Drugs, 2008) [PMID:18729537]
_Worker-drafted node — pending editorial review._
Connections
febuxostat is a side effect of
Sources
- Febuxostat compared with allopurinol in patients with hyperuricemia and gout. (2005) pubmed
- Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. (2020) pubmed
- Febuxostat. (2008) pubmed
- Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China. (2025) pubmed
- Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials. (2024) pubmed
- The role of febuxostat in gout. (2019) pubmed
- Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report. (2025) pubmed
- Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. (2008) pubmed
- Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial. (2024) pubmed
- Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3-5 patients with asymptomatic hyperuricemia: a network meta-analysis. (2025) pubmed